Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Cuneo

Showing results (101-110 of 185) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|June 23, 2017
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomideRossana Maffei, Stefania Fiorcari, Silvia Martinelli, et al.
Hematological Oncology|March 8, 2018
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleedingGiuseppe Boriani, Paolo Corradini, Antonio Cuneo, et al.
Oncotarget|April 22, 2017
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessGian Matteo Rigolin, Luca Formigaro, Maurizio Cavallari, et al.
Experimental Hematology|November 12, 2013
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemiaRossana Maffei, Stefania Fiorcari, Jenny Bulgarelli, et al.
BMJ Supportive & Palliative Care|May 4, 2021
Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factorsLaura B Oswald, Adriano Venditti, David Cella, et al.
Blood|January 17, 2012
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parametersGian Matteo Rigolin, Francesca Cibien, Sara Martinelli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 23, 2016
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapySara Martinelli, Antonio Cuneo, Luca Formigaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2013
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantationFrancesco Lanza, Diana C Campioni, Andrzej Hellmann, et al.
Oncotarget|October 23, 2018
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemiaMaurizio Cavallari, Francesco Cavazzini, Antonella Bardi, et al.
Pageof 19

Showing results (101-110 of 185) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|June 23, 2017
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomideRossana Maffei, Stefania Fiorcari, Silvia Martinelli, et al.
Hematological Oncology|March 8, 2018
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleedingGiuseppe Boriani, Paolo Corradini, Antonio Cuneo, et al.
Oncotarget|April 22, 2017
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessGian Matteo Rigolin, Luca Formigaro, Maurizio Cavallari, et al.
Experimental Hematology|November 12, 2013
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemiaRossana Maffei, Stefania Fiorcari, Jenny Bulgarelli, et al.
BMJ Supportive & Palliative Care|May 4, 2021
Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factorsLaura B Oswald, Adriano Venditti, David Cella, et al.
Blood|January 17, 2012
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parametersGian Matteo Rigolin, Francesca Cibien, Sara Martinelli, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 23, 2016
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapySara Martinelli, Antonio Cuneo, Luca Formigaro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysisFausto Castagnetti, Nicoletta Testoni, Simona Luatti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 31, 2013
Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantationFrancesco Lanza, Diana C Campioni, Andrzej Hellmann, et al.
Oncotarget|October 23, 2018
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemiaMaurizio Cavallari, Francesco Cavazzini, Antonella Bardi, et al.
Pageof 19